Pacific Edge (NZX, ASX PEB) has announced the acceptance for publication of new clinical evidence showing significant improvements in the performance of its genomic diagnostic Cxbladder tests.
The results of the study are to be published in the American Urological Association (AUA) Journal of Urology and show an improvement in all performance characteristics over the existing versions of Cxbladder.
Chief Executive Dr Peter Meintjes says, “By adding DNA biomarkers, we have developed Cxbladder Detect+, a single product for hematuria evaluation that can assist clinicians to safely and reliably rule in or rule out the presence of bladder cancer for any hematuria patient at any point in the patient care pathway.”
See more
